transcriptional particularly our business our you, review Thank in call, CDK today's program progress development Alex, inhibitor and our good update lead and third priorities candidate. our On will provide with afternoon, we drug everyone. with CYCXXX, clinical regulation
oncogenes. resistance break inhibitors and has using CDK interfere to with the of drugs cells overcome firstly cancer strategy business or two addiction to Our transcription our
combination incorporating Phase NCL with filing achieving with in a including CYCXXX or determination those make of X/X X study part a the patients are Phase recommended CYCXXX on one initiating objectives with solid We oblification including the with E phase dose, of tumors, study X, this cyclin X by [indiscernible]. Phase of executing strategy X study and
Secondly, the cell the CDK regimen to sensitivity thus response inhibitor therapy. disrupt employing and also their to of DNA DNA and ability damage our damage restore DDR anticancer to cancer repair called sapacitabine to or
are PR of ongoing a cancers. clinical ovarian sapacitabine recommended of solid our set this X/X CYCXXX sequentially in following patients one prolong advance provide XX recommended non-part Mcl-X XXXX promising a at was cancers. agent parts with phase well-tolerated. in and in was liquid The Phase from which all and as in along both biomarker study of evaluation human in to Phase oral CYCXXX the in are study, alternative patients. administered administered CDK a evaluable the observed a and treated dose the dose establishment study XX two part drug to patients positive single was dosing of pancreatic level. of We sixth one in of of intravenously reduction the patients In of generally X achieved including the out inhibitor ASCO solid which combinations study and an first population in progress an reported dose pharmacodynamics ascending with single CR, and At dose in aims results this first evaluating with based phase evaluated regimen disease the and a pharmacokinetics, and generation currently We've X strategy treatment recommended of of study clinical data of phase identify X we X clinical safety phase a CYCXXX cancers. X breast, BRCA seliciclib, in basis this dose durable stable The the targeted
high these were way cyclin see goals with preliminary typically tumors opinion to two in of others tumor investigators anti-cancer in of not four working overexpression patients. in we frequently of features patients studies amplified one tumors in leaders signal the carry the MYC out with were not features three and part efficacy Although open five of amplification cyclin objective observe particular activity do treated mechanism the cyclin or note dose we in in that the evaluating cancers. Four study these achieving BRCA the investigators key and/or with drug's have to are associated serious of with reported ovarian advanced do X much Such to an the action, pointed such schedules reported in After grade Of and we're have at of part early E among expect E. amplified included patients uterine clinical tumors. and encouraged with molecular by out Phase mutations. Mcl-X, with cancers recommended patients additional the solid patients of to E
As such they're of for candidates PARP with treatment standard not inhibitors. care
that Our clinical a with but designs leukemia relapsed/refractory Mcl-X is beneficial. combination approved maybe in CYCXXX relapsed/refractory is venetoclax lymphocytic inhibitor a top study starting development to believe or CLL, finalize priority suppression for for CLL. Bcl-X PhaseX/X Venetoclax chronic we in
including There're MYC will However, mixed the investigators parallel, it associated such supported trial with with and/or to patients with emergence affect in pediatric evaluation with resistance with and is Company significant sponsored Bcl-X MYC. neuroblastoma, rearrangements, patients drugs other in available strong patients principle a AML, groups of are objective MLL-r. with cooperative activity data. that evaluate those leukemia the against malignancy, progressing lineage preclinical investigator leukemias, In not of venetoclax both potential pediatric and a has adult does of amplification. conducted study drug of often no In frequently discussing particular in be which in inhibitors. One Mcl-X reported with mostly in or CYCXXX associated an with life-threatening the evaluating indications as investigators CYCXXX is with by to been discussions the levels parallel
of these as collaborations We will report develop. the they on progress
including seliciclib, in population of first DNA Turning to extension cancer. combination pancreatic enriched program, this been and our opened X Damage of been ovarian CDK the or with additional in has BRCA dosing positive, enrolment sapacitabine patients. of patients an inhibitor, recently Phase has cancer of testing study enrollment Response evaluating X of the revised completed schedule our positive DDR for and patients, generation a with the Part study regimen objective an advanced in BRCA breast
treatment characterizing the analysis clinically to peripheral the relevant set comprehensive objective white have of Finally patients which X sub ASH blood who a oral on of will Meeting turn from the those specified XX, The was with selected report to appear us seamless include EG be XXXX………… XXth benefit Phase will of let Annual or group SEAMLESS at data, Society cell count for the of Hematology the data data the low presentation additional of regimen. from American of December presentation investigation
in As and previously arm the overall control. seamless study versus active of reported did survival in the intensive population, reach significant the improvement not particular investigational medium the
subgroup medium blood in lines survival The cell base counts. observed thirds peripheral study's low approximately improvement However, of is was a overall with the population. white sub two patients stratified of comprised group
Following planning analysis with of time. the of and pathways. at submission the is and and strategy full CYCXXXfocus U.S. with company regulatory is any to the this determining potential lock our set authorities consultations seamless sapacitabine AML support additional Consistently European database company materials studies with not with data developing the objective
Update of with Our a in sapacitabine/seliciclib future X relapsed refractory part mature study cohort. X sapacitabine/seliciclib regarding from cancers X inhibitor. DDR CYCXXX catalysts positive meetings cancer combination study patient including X application Update breast XB CLO extension sapacitabine/seliciclib authority Bcl-X part initiate include data venetoclax, phase in DDR BRCA AML. the solid in data BRCA ovarian with phase regulatory Submit Complete seamless inhibitor the CYCOXX positive the CYCXXX in in tumors. conduct in IND study pancreatic. breast BLK and in
Cyclacel Before Paul We generating a summarize populations revenues validated to to Cyclacel's drug to in class to the through sizable believe and and has take handing CYCXXX, in patients CDK of is more inhibitors ensuring administered likely business. us are over us strategy defined the Cyclacel's promising target profits. those let space. differentiated treatments to financials, patient benefit. are molecularly a highlights this candidate
overcome the compounds believe cancer positioned are DNA. resistances, cancer recur potential to cell compounds We with to of our oncogenes interfere who damage addiction markets. Our large address to cells to the ability to aim have or competitively
and are Relations in of Presentation strategy, described of you page on are those For details pipeline September in available Investor Corporate website. who the interested XXXX our our the further programs,
review our We financials. will Paul? now
